Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: A cohort study from Rio de Janeiro, Brazil

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Calvet, Guilherme Amaral ^a   Velasque, Luciane ^a,b   Luz, Paula Mendes ^a   Cardoso, Sandra Wagner ^a   Derrico, Monica ^a   Moreira, Ronaldo Isméio ^a   Vasconcelos De Andrade, Angela Cristina ^a   Cytryn, Andrea ^a   Pires, Elaine ^a   Veloso, Valdiléa Gonçalves ^a   Grinsztejn, Beatriz ^a   Friedman, Ruth Khalili ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMENORRHEA; ANTIVIRAL THERAPY; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; TREATMENT DURATION; VIRUS LOAD; BLOOD; CD4+ T LYMPHOCYTE; DRUG EFFECTS; FOLLOW UP; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MENOPAUSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TRENDS; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MENOPAUSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84895898916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089299     Document Type: Article

References (37)

1. UNAIDS World AIDS Day report (2011) Available: http://www.unaids.org/en/ media/unaids/contentassets/documents/unaidspublication/2011/jc2216-worldaidsday- report-2011-en.pdf.Accessed 28 August 2013.
2. Instituto Brasileiro de Geografia e Estatística - IBGE (Brazil) (2002) Perfil dos Idosos Responsáveis pelos Domicílios no Brasil 2000. Rio de Janeiro. Available: http://www.ibge.gov.br/home/estatistica/ populacao/perfilidoso/perfidosos2000.pdf. Accessed 28 September 2013.
3. Lazarus JV, Nielsen KK (2010) HIV and people over 50 years old in Europe. HIV Med 11: 479-481.
4. Cejtin HE (2012) Care of the human immunodeficiency virus-infected menopausal woman. Am J Obstet Gynecol 207: 87-93.
5. Napravnik S, Poole C, Thomas JC, Eron JJ, Jr. (2002) Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 31: 11-19.
6. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, et al. (2002) Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 35: 313-322. (Pubitemid 34800281)
7. Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, et al. (2011) Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther 16: 1057-1062.
8. Haynes L, Maue AC (2009) Effects of aging on T cell function. Curr Opin Immunol 21: 414-417.
9. Yao G, Hou Y (2004) Recent advances for research on effect of estrogen on immune system. Wei Sheng Yan Jiu 33: 759-761.
10. Gameiro CM, Romao F, Castelo-Branco C (2010) Menopause and aging: changes in the immune system-a review. Maturitas 67: 316-320.
11. Oertelt-Prigione S (2012) The influence of sex and gender on the immune response. Autoimmun Rev 11: A479-485.
12. Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, et al. (2010) Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naive HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials 11: 340-350.
13. Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, et al. (2011) Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 16: 805-814.
14. Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA (2008) Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 22: 2331-2339.
15. Balestre E, Eholie SP, Lokossue A, Sow PS, Charurat M, et al. (2012) Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS 26: 951-957.
16. Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, et al. (2009) Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis 49: 473-476.
17. van Benthem BH, Vernazza P, Coutinho RA, Prins M, European Study on the Natural History of HIV Infection in Women, et al. (2002) The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. AIDS 16: 919-924. (Pubitemid 34409016)
18. Cardoso SW, Grinsztejn B, Velasque L, Veloso VG, Luz PM, et al. (2010) Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses 26: 865-874.
19. Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, et al. (2011) Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr 57 Suppl 3: S171-178.
20. Grinsztejn B, Bastos FI, Veloso VG, Friedman RK, Pilotto JH, et al. (2006) Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS 17: 473-478. (Pubitemid 44049675)
21. Friedman RK, Bastos FI, Leite IC, Veloso VG, Moreira RI, et al. (2011) Pregnancy rates and predictors in women with HIV/AIDS in Rio de Janeiro, Southeastern Brazil. Rev Saude Publica 45: 373-381.
22. (1996) Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 866: 1-107.
23. Centers for Diseases Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41: 1-19.
24. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, et al. (2004) Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 4: 46.
25. Wellons MF, Sanders L, Edwards LJ, Bartlett JA, Heald AE, et al. (2002) HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 50: 603-607. (Pubitemid 34298746)
26. Yan J, Soon G, Zhou S, Min M, Chan-Tack K, et al. (2013) Differences by age for women in the response to initial HAARTs: Meta-analysis from clinical studies submitted to the FDA (2000-2010). Third International Workshop on HIV and Women. Proceedings. Toronto, Canada, 2013. Reviews in Antiviral Therapy & Infectious Diseases 1: O-11.
27. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, et al. (2007) Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 167: 684-691. (Pubitemid 46598461)
28. Newman J, Iriondo-Perez J, Hemingway-Foday J, Freeman A, Akam W, et al. (2012) Older Adults Accessing HIV Care and Treatment and Adherence in the IeDEA Central Africa Cohort. AIDS Res Treat 2012: 725713.
29. Abrogoua DP, Kablan BJ, Kamenan BA, Aulagner G, N'Guessan K, et al. (2012) Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence 6: 227-237.
30. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, et al. (2004) Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 18: 2029-2038. (Pubitemid 39463356)
31. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, et al. (2010) Virologic and immunologic response to HAART, by age and regimen class. AIDS 24: 2469-2479.
32. Maman D, Pujades-Rodriguez M, Nicholas S, McGuire M, Szumilin E, et al. (2012) Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/mul. AIDS 26: 1393-1398.
33. Blanco JR, Jarrin I, Vallejo M, Berenguer J, Solera C, et al. (2012) Definition of advanced age in HIV infection: looking for an age cut-off. AIDS Res Hum Retroviruses 28: 1000-1006.
34. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, et al. (2012) CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 9: e1001194.
35. Patterson K, Napravnik S, Eron J, Keruly J, Moore R (2007) Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med 8: 406-410. (Pubitemid 47163274)
36. Hermes A, Squires K, Fredrick L, Martinez M, Pasley M, et al. (2012) Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir- containing antiretroviral therapy in HIV-1-infected women. HIV Clin Trials 13: 308-323.
37. Torres TS, Cardoso SW, Velasque LS, Veloso VG, Grinsztejn B (2014) Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. Braz J Infect Dis 18: 34-41.